CA2178021C - Produit de remplacement du tabac - Google Patents

Produit de remplacement du tabac

Info

Publication number: CA2178021C
Authority: CA; Canada
Prior art keywords: nicotine; dosage form; patient; mouth; matrix
Prior art date: 1996-04-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA 2178021

Other languages

English (en)

Other versions

CA2178021A1 (fr

Inventor

Theodore H. Stanley

Brian I. Hague

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Utah Research Foundation Inc

Original Assignee

University of Utah Research Foundation Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-19

Filing date

1996-06-03

Publication date

1999-09-28

1996-04-19 Priority claimed from US08/636,828 external-priority patent/US5824334A/en

1996-06-03 Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc

1997-10-20 Publication of CA2178021A1 publication Critical patent/CA2178021A1/fr

1999-09-28 Application granted granted Critical

1999-09-28 Publication of CA2178021C publication Critical patent/CA2178021C/fr

2016-06-03 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

235000002637 Nicotiana tabacum Nutrition 0.000 title description 22
244000061176 Nicotiana tabacum Species 0.000 title 1
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 284
229960002715 nicotine Drugs 0.000 claims abstract description 279
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 279
239000002552 dosage form Substances 0.000 claims abstract description 104
239000000203 mixture Substances 0.000 claims abstract description 12
238000003780 insertion Methods 0.000 claims abstract description 7
230000037431 insertion Effects 0.000 claims abstract description 7
210000000214 mouth Anatomy 0.000 claims description 51
239000011159 matrix material Substances 0.000 claims description 50
239000000463 material Substances 0.000 claims description 29
239000003814 drug Substances 0.000 claims description 28
229940079593 drug Drugs 0.000 claims description 27
238000010521 absorption reaction Methods 0.000 claims description 24
238000000034 method Methods 0.000 claims description 19
210000004369 blood Anatomy 0.000 claims description 17
239000008280 blood Substances 0.000 claims description 17
239000007787 solid Substances 0.000 claims description 16
239000006172 buffering agent Substances 0.000 claims description 14
239000000843 powder Substances 0.000 claims description 10
239000002585 base Substances 0.000 claims description 8
210000004400 mucous membrane Anatomy 0.000 claims description 8
210000003800 pharynx Anatomy 0.000 claims description 8
210000003296 saliva Anatomy 0.000 claims description 8
210000003238 esophagus Anatomy 0.000 claims description 7
230000001965 increasing effect Effects 0.000 claims description 7
210000002966 serum Anatomy 0.000 claims description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
238000004090 dissolution Methods 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
150000001720 carbohydrates Chemical class 0.000 claims description 5
239000002195 soluble material Substances 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 4
239000012458 free base Substances 0.000 claims description 4
LDMPZNTVIGIREC-ZGPNLCEMSA-N nicotine bitartrate Chemical compound O.O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.CN1CCC[C@H]1C1=CC=CN=C1 LDMPZNTVIGIREC-ZGPNLCEMSA-N 0.000 claims description 3
229940069688 nicotine bitartrate Drugs 0.000 claims description 3
AIBWPBUAKCMKNS-PPHPATTJSA-N 2-hydroxybenzoic acid;3-[(2s)-1-methylpyrrolidin-2-yl]pyridine Chemical compound OC(=O)C1=CC=CC=C1O.CN1CCC[C@H]1C1=CC=CN=C1 AIBWPBUAKCMKNS-PPHPATTJSA-N 0.000 claims description 2
SDVKWBNZJFWIMO-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CN1CCCC1C1=CC=CN=C1.OC(=O)CC(O)(C(O)=O)CC(O)=O SDVKWBNZJFWIMO-UHFFFAOYSA-N 0.000 claims description 2
HDJBTCAJIMNXEW-PPHPATTJSA-N 3-[(2s)-1-methylpyrrolidin-2-yl]pyridine;hydrochloride Chemical compound Cl.CN1CCC[C@H]1C1=CC=CN=C1 HDJBTCAJIMNXEW-PPHPATTJSA-N 0.000 claims description 2
YHBIGBYIUMCLJS-UHFFFAOYSA-N 5-fluoro-1,3-benzothiazol-2-amine Chemical compound FC1=CC=C2SC(N)=NC2=C1 YHBIGBYIUMCLJS-UHFFFAOYSA-N 0.000 claims description 2
159000000011 group IA salts Chemical class 0.000 claims description 2
BRTHFWPGJMGHIV-UHFFFAOYSA-L zinc;3-(1-methylpyrrolidin-2-yl)pyridine;dichloride;hydrate Chemical compound O.[Cl-].[Cl-].[Zn+2].CN1CCCC1C1=CC=CN=C1 BRTHFWPGJMGHIV-UHFFFAOYSA-L 0.000 claims description 2
239000011247 coating layer Substances 0.000 claims 2
239000010410 layer Substances 0.000 claims 2
QLDPCHZQQIASHX-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound OC(=O)C(O)C(O)C(O)=O.CN1CCCC1C1=CC=CN=C1 QLDPCHZQQIASHX-UHFFFAOYSA-N 0.000 claims 1
MQWJVKLIBZWVEL-XRIOVQLTSA-N 3-[(2s)-1-methylpyrrolidin-2-yl]pyridine;dihydrochloride Chemical compound Cl.Cl.CN1CCC[C@H]1C1=CC=CN=C1 MQWJVKLIBZWVEL-XRIOVQLTSA-N 0.000 claims 1
238000005538 encapsulation Methods 0.000 claims 1
230000002708 enhancing effect Effects 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
238000002844 melting Methods 0.000 claims 1
230000008018 melting Effects 0.000 claims 1
235000019504 cigarettes Nutrition 0.000 abstract description 39
230000000391 smoking effect Effects 0.000 abstract description 39
230000000638 stimulation Effects 0.000 abstract description 4
230000005586 smoking cessation Effects 0.000 abstract description 2
241000208125 Nicotiana Species 0.000 description 21
235000019788 craving Nutrition 0.000 description 18
230000004888 barrier function Effects 0.000 description 17
230000000694 effects Effects 0.000 description 17
239000002609 medium Substances 0.000 description 14
239000004615 ingredient Substances 0.000 description 10
230000001055 chewing effect Effects 0.000 description 9
-1 disodium hydrogen Chemical class 0.000 description 9
210000002381 plasma Anatomy 0.000 description 9
239000007937 lozenge Substances 0.000 description 8
239000002245 particle Substances 0.000 description 8
239000000779 smoke Substances 0.000 description 8
210000004379 membrane Anatomy 0.000 description 7
239000012528 membrane Substances 0.000 description 7
239000011148 porous material Substances 0.000 description 7
238000002156 mixing Methods 0.000 description 6
239000000126 substance Substances 0.000 description 6
239000003826 tablet Substances 0.000 description 6
230000008878 coupling Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
150000002500 ions Chemical class 0.000 description 5
239000007788 liquid Substances 0.000 description 5
239000007922 nasal spray Substances 0.000 description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
206010028813 Nausea Diseases 0.000 description 4
230000008901 benefit Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
239000003292 glue Substances 0.000 description 4
230000008693 nausea Effects 0.000 description 4
230000008569 process Effects 0.000 description 4
230000000717 retained effect Effects 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000011734 sodium Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
239000004677 Nylon Substances 0.000 description 3
230000006399 behavior Effects 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
230000036765 blood level Effects 0.000 description 3
230000003139 buffering effect Effects 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
239000000945 filler Substances 0.000 description 3
230000007794 irritation Effects 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
229920001778 nylon Polymers 0.000 description 3
239000012466 permeate Substances 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
230000009747 swallowing Effects 0.000 description 3
238000011282 treatment Methods 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
229920004934 Dacron® Polymers 0.000 description 2
239000004097 EU approved flavor enhancer Substances 0.000 description 2
208000018737 Parkinson disease Diseases 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
238000004026 adhesive bonding Methods 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000001427 coherent effect Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
235000019264 food flavour enhancer Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
230000036541 health Effects 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000007774 longterm Effects 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
229940097496 nasal spray Drugs 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
239000005020 polyethylene terephthalate Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
239000011253 protective coating Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 description 1
GHPYJLCQYMAXGG-WCCKRBBISA-N (2R)-2-amino-3-(2-boronoethylsulfanyl)propanoic acid hydrochloride Chemical compound Cl.N[C@@H](CSCCB(O)O)C(O)=O GHPYJLCQYMAXGG-WCCKRBBISA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
101100534575 Caenorhabditis elegans sucl-1 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000031361 Hiccup Diseases 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
101150081532 KLK8 gene Proteins 0.000 description 1
101100219404 Mus musculus Calcrl gene Proteins 0.000 description 1
101100277637 Mus musculus Dffa gene Proteins 0.000 description 1
206010057852 Nicotine dependence Diseases 0.000 description 1
208000007117 Oral Ulcer Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
208000000323 Tourette Syndrome Diseases 0.000 description 1
208000016620 Tourette disease Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
230000037374 absorbed through the skin Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
230000002567 autonomic effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000037058 blood plasma level Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
239000003729 cation exchange resin Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
238000002485 combustion reaction Methods 0.000 description 1
239000002131 composite material Substances 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229950006073 cotinine Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000001035 drying Methods 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
230000003028 elevating effect Effects 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
229920006226 ethylene-acrylic acid Polymers 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000000609 ganglia Anatomy 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
208000024798 heartburn Diseases 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000000416 hydrocolloid Substances 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
206010021654 increased appetite Diseases 0.000 description 1
238000001746 injection moulding Methods 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
238000007689 inspection Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
230000002352 nonmutagenic effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000003825 pressing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000004800 psychological effect Effects 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000009467 reduction Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
231100001229 severe poisoning Toxicity 0.000 description 1
238000004088 simulation Methods 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
229940124535 smoking cessation aid Drugs 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
229960004025 sodium salicylate Drugs 0.000 description 1
229940074404 sodium succinate Drugs 0.000 description 1
ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
231100000925 very toxic Toxicity 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000002759 woven fabric Substances 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CA 2178021 1996-04-19 1996-06-03 Produit de remplacement du tabac Expired - Lifetime CA2178021C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/636,828 US5824334A (en)	1989-09-05	1996-04-19	Tobacco substitute
US08/636,828		1996-04-19

Publications (2)

Publication Number	Publication Date
CA2178021A1 CA2178021A1 (fr)	1997-10-20
CA2178021C true CA2178021C (fr)	1999-09-28

Family

ID=24553502

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2178021 Expired - Lifetime CA2178021C (fr)	1996-04-19	1996-06-03	Produit de remplacement du tabac

Country Status (4)

Country	Link
JP (1)	JP2784347B2 (fr)
AU (1)	AU681323B1 (fr)
CA (1)	CA2178021C (fr)
NO (1)	NO319057B1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040037879A1 (en) *	2001-11-02	2004-02-26	Adusumilli Prasad S.	Oral controlled release forms useful for reducing or preventing nicotine cravings
SE0202365D0 (sv) *	2002-08-05	2002-08-05	Pharmacia Ab	New formulation and use thereof
ES2285233T3 (es) *	2002-12-20	2007-11-16	Niconovum Ab	Un material en particulas que contiene nicotina y celulosa microcristalina fisicamente y quimicamente estable.
EA012306B1 (ru) *	2003-01-24	2009-08-28	Магле Холдинг Аб	Композиционный материал для доставки через слизистые оболочки
SE0302947D0 (sv)	2003-01-24	2003-11-07	Magle Ab	A composition material for transmucosal delivery
BRPI1010548A2 (pt)	2009-05-11	2016-03-15	Us Smokeless Tobacco Co	compósito flavorizante encapsulado, compósito de adoçante artificial encapsulado e produto.
FR2987561B1 (fr) *	2012-03-02	2014-04-11	Pf Medicament	Dispositif transdermique comprenant des micro-particules poreuses
UA116440C2 (uk) *	2012-03-27	2018-03-26	Нікоссіно Аб	Композиція нікотину
US10532046B2 (en) *	2015-12-03	2020-01-14	Niconovum Usa, Inc.	Multi-phase delivery compositions and products incorporating such compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2230439A (en) *	1989-04-20	1990-10-24	Alec Stanley Walter Shaw	Nicotine lozenges
US5048544A (en) *	1990-08-10	1991-09-17	Robert Mascarelli	Cigarette substitute
GB9111224D0 (en) *	1991-05-24	1991-07-17	Charwell Consumer Prod	Smoking substitute preparation

1996
- 1996-06-03 CA CA 2178021 patent/CA2178021C/fr not_active Expired - Lifetime
- 1996-06-04 AU AU54700/96A patent/AU681323B1/en not_active Expired
- 1996-07-03 NO NO19962808A patent/NO319057B1/no not_active IP Right Cessation
- 1996-08-01 JP JP8203557A patent/JP2784347B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
NO962808L (no)	1997-10-20
NO319057B1 (no)	2005-06-13
CA2178021A1 (fr)	1997-10-20
JPH09286729A (ja)	1997-11-04
NO962808D0 (no)	1996-07-03
JP2784347B2 (ja)	1998-08-06
AU681323B1 (en)	1997-08-21

Legal Events

Date	Code	Title	Description
1996-06-27	EEER	Examination request
2016-08-07	MKEX	Expiry	Effective date: 20160603

Publication	Publication Date	Title
US5824334A (en)	1998-10-20	Tobacco substitute
US5783207A (en)	1998-07-21	Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine
JP5845194B2 (ja)	2016-01-20	ニコチン含有ソフトゼラチントローチ
US5288498A (en)	1994-02-22	Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US5855908A (en)	1999-01-05	Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient
AU668004B2 (en)	1996-04-18	Compositions and methods of manufacture of oral dissolvable medicaments
US20020160043A1 (en)	2002-10-31	Compositions and method of manufacture for oral dissolvable dosage forms
US8846075B2 (en)	2014-09-30	Composition material for transmucosal delivery
US6893654B2 (en)	2005-05-17	Two-stage transmucosal medicine delivery system for symptom relief
US4863737A (en)	1989-09-05	Compositions and methods of manufacture of compressed powder medicaments
JP2602043B2 (ja)	1997-04-23	ニコチン含有流動媒質を含む口経投与用カプセル
US20020002189A1 (en)	2002-01-03	Nicotine therapy method and oral carrier for assuaging tobacco-addiction
JP2012505878A (ja)	2012-03-08	複数部分口内剤形及びその使用
KR20050107401A (ko)	2005-11-11	점막투과 전달용 조성물 재료
WO2003090798A1 (fr)	2003-11-06	Administration d'antimigraineux en sprays ou aerosols sublinguaux a base de dihydroergotamine
EP0745380B1 (fr)	2005-08-03	Substitut de tabac
CA2178021C (fr)	1999-09-28	Produit de remplacement du tabac
WO2003004002A1 (fr)	2003-01-16	Administration sublinguale de dihydroergotamine pour traiter la migraine
US20070190117A1 (en)	2007-08-16	Buccal formulations of galanthamine and uses thereof